CORDIS
EU research results

CORDIS

English EN

PROMOTING ACTIVE AGEING: FUNCTIONAL NANOSTRUCTURES FOR ALZHEIMER’S DISEASE AT ULTRA-EARLY STAGES.

Objective

Alzheimer’s disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. Progressive aging of EU population will increase the magnitude of this problem in the next decades. Currently, there is not an effective method for the early diagnosis of AD. Therefore, there is an urgent need to develop new effective early diagnostic and therapeutic strategies to help in delaying the appearance of the most adverse symptoms of this disease. To defeat this challenge, PANA project bases its approach on the importance of tau oligomers in the early pathophysiological processes of AD. The effective strategy will be based on two fundamental pillars; on one hand, efforts will be focused on multimodal PET/MRI imaging which is gaining relevance as the best solution for diagnostic purposes due to the complementary advantages of both technologies, combining the high structural characterization of tissue provided by MRI with the enhanced sensitivity of PET imaging. On the other hand, the challenging development of a theragnostic nanostructures will be focused on tau oligomers detection, which would have to deliver theragnostic agents into the brain to provide in situ diagnostic and therapeutic effects. Therefore, PANA project focuses on developing theranostic nanostructures that specifically recognize very-early molecular markers of AD, and can be detected by means of non-invasive imaging methodologies (MRI and/or PET, which are already common techniques accessible in most hospitals) and eventually provide a therapeutic action if needed.
To achieve this goal, we propose a unique consortium which combines neuroscientists, nanotechnologists, molecular imaging experts, clinicians and Small/Medium/Large Enterprises in an effort to use smart nanoparticles engineered with multifunctional biomaterial to provide new very-early diagnostic tools for AD, a vital medical/social problem in EU.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

SERVIZO GALEGO DE SAUDE

Address

Edificio Administrativo San LÁZaro
15703 Santiago De Compostela

Spain

Activity type

Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)

EU Contribution

€ 1 573 537,50

Participants (10)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

EU Contribution

€ 529 750

LABORATORIO IBERICO INTERNACIONAL DE NANOTECNOLOGIA

Portugal

EU Contribution

€ 319 497,50

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 1 094 875

reMYND NV

Belgium

EU Contribution

€ 482 720

STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA

Portugal

EU Contribution

€ 463 030

STICHTING VU

Netherlands

EU Contribution

€ 762 125

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 1 055 500

ROCHE DIAGNOSTICS SL

Spain

EU Contribution

€ 253 437,50

BIOTECHPHARMA

Lithuania

EU Contribution

€ 845 250

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON

Spain

EU Contribution

€ 396 250

Project information

Grant agreement ID: 686009

Status

Ongoing project

  • Start date

    1 March 2016

  • End date

    28 February 2021

Funded under:

H2020-EU.2.1.3.

  • Overall budget:

    € 7 775 972,50

  • EU contribution

    € 7 775 972,50

Coordinated by:

SERVIZO GALEGO DE SAUDE

Spain